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Abstract
The global problem of microbial resistance to antibiotics has resulted in an urgent need to
develop new antimicrobial agents. Natural antimicrobial peptides are considered promising
candidates for drug development. Echinoderms, which rely on innate immunity factors in
the defence against harmful microorganisms, are sources of novel antimicrobial peptides.
This study aimed to isolate and characterise antimicrobial peptides from the Edible sea
urchin Echinus esculentus. Using bioassay-guided purification and cDNA cloning, three
antimicrobial peptides were characterised from the haemocytes of the sea urchin; two het-
erodimeric peptides and a cysteine-rich peptide. The peptides were named EeCentrocin 1
and 2 and EeStrongylocin 2, respectively, due to their apparent homology to the published
centrocins and strongylocins isolated from the green sea urchin Strongylocentrotus droe-
bachiensis. The two centrocin-like peptides EeCentrocin 1 and 2 are intramolecularly con-
nected via a disulphide bond to form a heterodimeric structure, containing a cationic heavy
chain of 30 and 32 amino acids and a light chain of 13 amino acids. Additionally, the light
chain of EeCentrocin 2 seems to be N-terminally blocked by a pyroglutamic acid residue.
The heavy chains of EeCentrocins 1 and 2 were synthesised and shown to be responsible
for the antimicrobial activity of the natural peptides. EeStrongylocin 2 contains 6 cysteines
engaged in 3 disulphide bonds. A fourth peptide (Ee4635) was also discovered but not fully
characterised. Using mass spectrometric and NMR analyses, EeCentrocins 1 and 2, EeS-
trongylocin 2 and Ee4635 were all shown to contain post-translationally brominated Trp res-
idues in the 6 position of the indole ring.
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1 Introduction
Increasing numbers of pathogenic bacterial strains are becoming resistant to antibiotics. More
people in US hospitals now die from methicillin-resistant Staphylococcus aureus (MRSA) infec-
tions than HIV/AIDS and tuberculosis combined [1]. It is therefore a pressing need to find and
develop antimicrobial agents as alternatives to classical antibiotics. Antimicrobial peptides
(AMPs) are part of the immune system in both plants and animals and they are considered to
constitute an evolutionarily ancient response to fight invading pathogenic microorganisms [2].
AMPs are evolutionary conserved and gene-encoded peptides, usually cationic, short (12–45)
amino acid chains [3]. Most AMPs exhibit broad-spectrum activity towards both Gram-posi-
tive and Gram-negative bacteria. In contrast to commercial antibiotics where the development
of resistance is a problem, bacterial resistance towards AMPs is much less pronounced [1, 4].
Because of their propensity to be rapidly metabolised in the gastrointestinal tract, peptides
have been considered poor drug candidates. This problem has diminished somewhat in recent
years with the development of new synthetic strategies to improve bioavailability and reduce
metabolism of peptides, and bolstered by the development of alternative routes of administra-
tion [5, 6]. A large number of peptide-based drugs are now in clinical trials or being marketed,
including AMPs [5, 7]. Today, more than 2600 peptides have been registered in the Antimicro-
bial Peptide Database [8], mainly from terrestrial sources. Marine invertebrates, although less
studied, have proven to be a promising source for discovering AMPs with novel scaffolds [9].
Echinoderms are exposed to relatively high bacterial levels because they are often found in
the photic zone where conditions for microbial growth are optimal. The survival of these
organisms relies on the production of efficient antimicrobial components to defend themselves
against microbial infections and fouling. As invertebrates in general [10], echinoderms do not
have an adaptive immune system like the one recognised in vertebrates where specific memory
towards pathogens is developed. Their innate defence system is mediated by the coelomocytes
and compounds like complement factors, lectins, lysozymes and AMPs [11–13].
A number of AMPs have previously been found in echinoderms [13–20]. Examples include
lysozymes that catalyse the hydrolysis of the peptidoglycans of the bacterial cell wall on Gram-
positive bacteria and act as non-specific innate immunity molecules [17, 18]. A 6 kDa AMP in
the coelomic fluid of the orange-footed sea cucumber, Cucumaria frondosa, was discovered but
no sequence was reported [20]. Several antibacterial peptides from the coelomic fluid of the
starfish Asterias rubens with masses around 2 kDa have also been discovered [19, 21]. Two of
these peptides were identified as fragments of the histone H2A molecule, two peptides were
identified as fragments of actin, and one was identified as a fragment of filamin A. A 5 kDa
peptide having antistaphylococcal biofilm properties was discovered in the coelomocytes of the
sea urchin Paracentrotus lividus [16]. The antibiofilm activity was suggested to be ascribed to
beta-thymosin like fragments [22]. From the coelomocytes of the sea urchin Strongylocentrotus
droebachiensis, two novel AMP families were characterised–the strongylocins [14] and the cen-
trocins [23]. The strongylocins are cysteine rich peptides containing three disulphide bonds
with MW in the 5.6–5.8 kDa range. Homologous genes have been discovered in S. purpuratus
and their deduced peptide sequences named SpStrongylocins. Recombinantly produced
SpStrongylocin analogues were also shown to be antibacterial [24]. The centrocins are a family
of heterodimeric AMPs ranging between 4.4 and 4.5 kDa in mass. The peptides consist of two
peptide chains: a 30 amino acid residue heavy chain (HC) and a 12 amino acid residue light
chain (LC) connected by a single disulphide bond. Bioactivity studies have shown that the cat-
ionic HC is responsible for the antimicrobial activity of these peptides [23]. The HC of centro-
cin 1 displays potent activity against both bacteria and fungi and display antiinflammatory
properties [25].
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The Edible sea urchin, Echinus esculentus (Fig 1) has been reported to contain antimicrobial
compounds [26], of which the quinone echinochrome-A has been identified [15, 27]. No
AMPs have yet been discovered. The aim of the present study was to search for, isolate and
characterise AMPs from the coelomocytes of the sea urchin E. esculentus. In this paper, we
present the discovery of new AMPs belonging to the centrocin and strongylocin family of
AMPs.
2 Materials and Methods
2.1 Ethics statement
All experiments performed in the present study were conducted in accordance with national
and international guidelines and the ethical guidelines of UiT The Arctic University of Norway.
For the haemolytic assay the collection of blood from a healthy donor was approved by the
regional committee for medical research (REK 2014/1653).
Fig 1. The Edible sea urchin, E. esculentus. Image credit: Runar Gjerp Solstad.
doi:10.1371/journal.pone.0151820.g001
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In Norway, collecting wild E. esculentus for research purposes does not require specific per-
mits. Our study does not involve endangered or protected species and sea urchins are not sub-
ject to any ethical animal use restrictions.
2.2 Animal collection and sample preparation
Live specimens of the Edible sea urchin, Echinus esculentus (Linnaeus, 1758) were collected
twice: 1) autumn of 2012 (70 specimens) and 2) autumn of 2013 (71 specimens), by divers off
the coast of Tromsø, Norway (70° 09.00' N 22° 15.22' E). The sea urchins were kept in continu-
ously flowing, unaltered seawater at 4–8°C until sample collection.
Coelomic fluid was sampled from the animals 1–4 weeks after animal collection by penetrat-
ing the peristome with a scalpel and pouring the content into Ca2+/Mg2+ free anti-coagulating
buffer [28] containing 70 mM EDTA and 50 mM imidazole in a 2:1 v/v ratio in 50 ml Falcon
tubes (BD Biosciences, CA, USA) on ice. In total, approximately 5500 ml coelomic fluid was
obtained. The mixture was subsequently centrifuged for 20 min at 4°C and 800 g. The pellet
(coelomocytes) was collected by pouring off the cell-free supernatant and kept at -70°C until
lyophilisation on a VirTis Genesis 35 EL freeze dryer (SP Industries, PA, USA) for 24 h. A total
amount of 12.2 g (dry weight) of coelomocytes was sampled. All sample weighing was per-
formed on a Sartorius Cubis MSA scale, Sartorius AG, Gottingen, Germany.
2.3 Extraction and purification
Lyophilised coelomocytes were extracted according to a previous protocol [29] with one modi-
fication: liquid-liquid extraction was carried out twice with 5% (w/v) lyophilised coelomocytes
in 60% acetonitrile (ACN) containing 0.1% trifluoroacetic acid (TFA) (both from Sigma-
Aldrich, MO, USA) for 24 h at 4°C. The combined extracts were partitioned into an aqueous
phase (approximate total of 100 ml) at the bottom and an ACN-rich phase (approximate total
of 150 ml) at the top by leaving it in a -20°C freezer for approximately 1 h. Both phases were
dried in a ScanSpeed 40 vacuum centrifuge (Labogene ApS, Denmark) for 24 h. The ACN-rich
phase was reconstituted in MQ-H2O (Millipore MA, USA) to a concentration of 10 mg/ml and
subjected to antibacterial activity testing.
The aqueous phase (5.49 g) was reconstituted to 10 mg/ml (549 ml) in 0.05% TFA/H2O (v/
v) and further subjected to solid phase extraction (SPE) on a reverse phase C18 35cc Sep-Pak
cartridge (Waters, MA, USA) according to [29] as follows. The extract was loaded onto the car-
tridge, previously conditioned with ACN, and equilibrated with 0.05% TFA/H2O (v/v). After
washing of the loaded extract with 0.05% TFA/H2O (v/v), four stepwise elutions were per-
formed with 10%, 40%, 80% and 100% ACN containing 0.05% TFA (v/v). The different frac-
tions collected were dried under vacuum, reconstituted to 10 mg/ml and tested for
antibacterial activity.
Due to its pronounced antibacterial activity (S1 Table), the 40% SPE eluate was further frac-
tionated by reversed-phase high-performance liquid chromatography (RP-HPLC) using a pre-
parative XBridge C18 (5 μm, 19 × 250 mm) column, a 717 autosampler, 600E pump system,
2996 photodiode array detector and an in-line degasser (Waters, MA, USA), all controlled by
the Millennium 32, v4.00 software (Scientific Equipment Source, Ontario, Canada). The flow
rate was set to 8 ml/min with an optimised HPLC protocol containing 0.05% TFA/H2O (v/v)
and 0.05% TFA/ACN (v/v). The protocol started with 10 min of 0.05% TFA/H2O (v/v) fol-
lowed by linear gradients increasing the 0.05% TFA/ACN (v/v) concentration from 0% to 18%
over 8 minutes, 18% to 32% over 32 minutes, 32% to 50% over four minutes, and finally wash-
ing with 0.05% TFA/ACN (v/v) for five min and re-equilibration with 0.05% TFA/H2O (v/v)
for five min. One minute (8 ml) fractions were collected automatically with a Gilson FC 204
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fraction collector (Gilson, WI, USA), dried in a ScanSpeed 40 vacuum centrifuge for 24 h, and
reconstituted in 500 μl MQ-H2O before antibacterial activity testing. Active fractions were ana-
lysed for purity, and bioactive peptides were detected using liquid chromatography UV-Vis
mass spectrometry (LC-PDA-MS, see section 2.6). Impure, active fractions were fractionated
again using the same experimental conditions but with fractions collected manually until pure
peptides (estimated purity>90%) were obtained.
To perform extended bioactivity screening and structural analyses of individual peptides,
more material of each peptide was needed. Multiple HPLC-runs, 23 injections in total, using
the same conditions as described above, and by collecting fractions manually, where therefore
performed. Pure peptide fractions (>90% as estimated with LC-MS) were pooled, lyophilised
and weighed. Test solutions for bioactivity were prepared with MQ-H2O.
2.4 Microbial strains and antimicrobial activity assays
Organic phase extract, SPE eluates and HPLC-fractions were screened for antibacterial activity
against two strains of Gram-positive and two strains of Gram-negative bacteria; Corynebacte-
rium glutamicum (ATCC 13032), Staphylococcus aureus (ATCC 9144), Pseudomonas aerugi-
nosa #1 (ATCC 27853) and Escherichia coli #1 (ATCC 25922). For extended antimicrobial
bioactivity screening, the following bacterial strains were used, three strains of Gram-positive
bacteria; S. epidermidis #1 (5179-R1) kindly provided by Holger Rohde [30], S. epidermidis #2,
RP62A (ATCC 35984) and Bacillus subtilis (ATCC 23857) in addition to the Gram-negative P.
aeruginosa #2, PA 01 (ATCC 15692, DSM 19880) and E. coli #2, NR 698 (MC4100/ptD4213).
Cultures stored at -80°C were smeared onto agar plates and cultured for 24 h at 35°C. One
colony of each bacterial strain was transferred to 5 ml liquid Müller-Hinton (MH, Difco, Law-
rence, KS, USA) medium in a glass tube and left shaking at room temperature overnight at 600
rpm. The cultures of actively growing bacteria (20 μl) were further inoculated in 5 ml MH
medium and left shaking for 2 h at room temperature. The antibacterial assays were performed
as previously described by [31]. Briefly, the bacterial cultures were diluted with medium to 1.3–
1.5 × 104 bacteria/ml final concentrations and an aliquot of 50 μl was added to each well in
96-well NunclonTM microtiter plates (Nagle Nunc Int., Denmark) preloaded with 50 μl test
sample solutions, i.e. extracts, eluates or peptides.
The test plates were incubated for 24 h at 35°C with optical density (OD595) recorded every
hour using an Envision 2103 multilabel reader, controlled by the Wallac Envision manager
(PerkinElmer, CT, USA). Antibacterial activity was defined as a sample showing>90% inhibi-
tion (as measured by optical density) compared to the negative (growth) controls, consisting of
bacteria and water. Oxytetracycline (20 μM) served as a positive (inhibition) control. The mini-
mum inhibitory concentration (MIC) was defined as the lowest concentration of a sample dis-
playing>90% inhibition.
The synthetic peptides (see section 2.11) were also screened for antifungal activity against
Candida albicans (ATCC 10231), Saccharomyces cerevisiae, Rhodotorula sp., Aureobasidium
pullulans and Cladosporium sp. The antifungal assay was performed as described previously
[32]. Briefly, fungal spores were dissolved in potato dextrose broth (Difco, Lawrence, KS, USA)
to a concentration of 4 × 105 spores/ml. The spores (50 μl) were inoculated on 96-well Nun-
clonTM microtiter plates containing the synthetic peptides (50 μl) dissolved in MQ-H2O. The
fungal growth and MIC were determined visually after incubation for 24 h at room tempera-
ture. MIC was defined as the lowest concentration of peptide giving no visible fungal growth.
The negative (growth) control contained medium and fungal solution.
ACN-phases and SPE eluates were tested with two-fold serial dilutions ranging from 5.0 to
0.005 mg/ml (5.0, 2.5, 1.25, 0.63, 0.31, 0.16, 0.08, 0.04, 0.02, 0.01, 0.005 mg/ml) whereas HPLC-
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fractions were tested undiluted for antibacterial activity. Pure, native peptides and synthetic
peptides (described in section 2.11) were tested for antimicrobial activity in concentrations
ranging from 100 to 0.1 μM in two-fold serial dilutions (100, 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78,
0.39, 0.20, 0.10 μM). Antimicrobial assays involving natural peptides (i.e. fractionated natural
material) were run only once due to limited quantities, whereas all other assays were run in
triplicates.
2.5 Haemolytic activity assay
Synthesised peptide analogues of EeCentrocin 1 and 2 were screened for eukaryotic cell-toxic-
ity with a haemolytic activity assay using human red blood cells as described previously [32].
The assay was performed on 96-well U-shaped microtiter plates (Nagle Nunc) with 50 μl pep-
tide sample, 40 μl phosphate-buffered saline (PBS) and 10 μl red blood cells. The final peptide
concentrations ranged from 100 to 0.1 μM in two-fold serial dilutions. After one hour of incu-
bation at 37°C in a shaker, the plate was centrifuged at 200 g for 5 min and the supernatants
(60 μl) were carefully transferred to a new flat-bottomed polycarbonate microtiter plate (Nagle
Nunc) and absorbance at 550 nm was measured on a Synergy H1 multimode reader (BioTek,
VT, USA). Cell suspension added 0.05% Triton X-100 (Sigma-Aldrich, MO, USA) in PBS
served as positive (100% haemolysis) control and cell suspension added PBS served as negative
(0% haemolysis) control. The percent haemolysis was calculated using the formula [(Asample-
Abaseline)/(Atriton-Abaseline)]×100. The experiment was performed in duplicates.
2.6 Two-dimensional liquid chromatography-mass spectrometry
analyses
Antibacterial HPLC fractions and SPE eluates were analysed by liquid chromatography
UV-Vis mass spectrometry (LC-PDA-MS) to identify antibacterial compounds and to perform
purity determinations. The LC-PDA-MS system consisted of a 2695 separation module, a Sun-
fire C18 (5μm, 2.1 × 100 mm) column, a 2998 PDA detector reading from 190 to 500 nm in 1.2
nm increments, and a Micromass ZQ mass spectrometer controlled by Masslynx v4.1 software
(all fromWaters, MA, USA). Compounds were eluted by running a linear gradient of increas-
ing ACN concentrations in water (both containing 0.05% TFA) from 5 to 50% over 16 min,
using a flow rate of 0.2 ml/min. Samples (5–20 μl) were introduced to the MS and analysed in
positive ESI mode. Ions were recorded in full scan mode in the 100–2000m/z-range (See S2
Table for typical MS settings). The mobile phases were the same as when running HPLC
(0.05% TFA/H2O (v/v) and 0.05% TFA/ACN (v/v)).
High-resolution mass spectrometry (HR-MS) was performed on a Thermo LTQ Orbitrap
XL with an electrospray ion source (ION-MAX) coupled to an Accela HPLC-system (Thermo
Fisher Scientific, MO, USA). A Supelco Ascentis Express (2.7 μm, 50 × 2.1 mm) C18 reverse
phase column was used. The datasets were deposited to The Mass Spectrometry Interactive
Virtual Environment repository (MassIVE, http://massive.ucsd.edu/ProteoSAFe/static/
massive.jsp) database with accession number MSV000079515.
2.7 Peptide sequencing
Enzyme digestion with endoproteinase Arg-C and Edman degradation were performed by
Eurosequence BV (Groningen, The Netherlands). Further sequence confirmation and elucida-
tion of modified amino acids was achieved through trypsin digestion or reduction/alkylation
and successive HR-MS. The protocol of Promega (Promega, WI, USA, available from http://
no.promega.com/resources/protocols/product-information-sheets/n/sequencing-grade-
modified-trypsin-frozen-protocol/) was followed regarding protease treatment. Briefly,
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peptides (700 μg) were dissolved in 6 M Guanidine HCl, 50 mM Tris HCl (pH 8) and 4 mM
Dithiothreitol (DTT, Sigma-Aldrich, MO, USA) in a reaction volume of 100 μl. The reaction
mixture was heated at 95°C for 20 min, cooled down to room temperature and added 550 μl
50 mMNH4HCO3 (pH 7.8). Porcine trypsin (Promega, WI, USA) was added at a 33:1 ratio
(peptide:trypsin, 700:21 μg, 15.000 u/mg) and incubated for 16 h at 37°C. High-resolution
LC-MS of the digested peptide was performed as previously described in section 2.6.
Reduction and alkylation was performed by dissolving ~20 nmol peptide in 100 μl 0.5 M
Tris HCl/1 mM EDTA/6M Guanidine HCl and adding 5 μl 2.2 M DTT (Sigma-Aldrich, MO,
USA). The peptide solution was flushed with N2 to prevent oxidation and incubated for 16 h at
37°C. After incubation, 5 μl 4-vinylpyridine (Sigma-Aldrich, MO, USA) was added to the solu-
tion and incubated for 20 min at 37°C. The reaction was stopped using RP-SPE with a C18 car-
tridge as previously described in section 2.3. The alkylated peptides were eluted with 80%
ACN/H2O (v/v) containing 0.05% TFA.
2.8 Characterisation of full length cDNA
Total RNA was isolated from the pooled coelomocytes of three animals using the QIAZolTM
reagent in accordance with the manufacturer’s instructions (QIAGEN, MD, USA). Reverse
transcription polymerase chain reaction (RT-PCR) was carried out using a rapid amplification
of cDNA ends (RACE) kit (Clontech, CA, USA). Total RNA (1 μg) was used as a template to
synthesise 5’ Ready-to-Go cDNA or 3’ Ready-to-Go cDNA according to the manufacturer’s
instructions.
In order to obtain partial cDNA sequence (3’ region), degenerate oligonucleotide primed
PCR (DOP-PCR) was performed as previously described [14]. Briefly, 0.5 μg of template (3’
Ready-to-Go cDNA), 10 × Optimised DyNAzyme™ Buffer, 1 μM of the forward primer EeCen
1DF (for EeCentrocin 1), EeCen 2DF (for EeCentrocin 2) or EeStrong 2DR (for EeStrongylocin
2) and reverse primers nested universal primer (NUP), 0.2 mM dNTP, 0.4 units DyNAzyme™
II DNA polymerase (Finnzymes, Finland) and water were mixed to bring the reaction volume
up to 25 μl. DOP-PCR was performed according to the following cycle: 94°C for 5 min, 35
cycles at 94°C for 30 sec, 55°C for 30 sec and 72°C for 2 min, followed by a final extension at
72°C for 10 min. The DOP-PCR products of 3’ region were cloned into pGEM1-T vector and
sequenced using primer Sp6 and T7. The correct sequences were confirmed by comparison of
deduced amino acid sequences with sequences obtained by Edman degradation. The 5’ region
of gene was cloned by using gene specific primer EeCen 1R, EeCen 2R or EeStrong 2R from the
3’ region and the primer NUP. The full-length nucleotide sequence was deduced based on the
overlapping sequence of the obtained RACE product with existing partial cDNA sequence.
Furthermore, the full length coding sequences were verified by PCR amplification using the
primers (EeCen 1 AF/AR for EeCentrocin 1, EeCen 2 AF/AR for EeCentrocin 2 or EeStrong 2
AF/AR for EeStrongylocin 2) situated at the extreme ends of the open reading frame. An over-
view of all primers is presented in S3 Table. The sequences were submitted to GenBank with
accession numbers KR494262, KR494263 and KR494264.
2.9 NMR analysis
NMR studies were performed on an Agilent (Varian) iNova spectrometer (Agilent Technolo-
gies, CA, USA) operating at 599.934 MHz for 1H equipped with a 5mm inverse cryogenically
enhanced HCN probe (2nd generation). All peptides were dissolved in D2O or H2O:D2O 9:1 in
3 mm Shigemi tubes matched for D2O. All acquired spectra and experimental parameters are
summarised in S4–S6 Tables and deposited in the Biological Magnetic Resonance Data Bank
(BMRB, http://www.bmrb.wisc.edu/) with accession number 26743.
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The acquired spectra were referenced on the residual solvent signal δH1 = 4.79 PPM and
δC13 from γH1:-γC13 = 3.976813 (water-d2). Data processing and figures were made using the
MestReNova v9.0.1 and NMRPipe v8.1 [33] software, and peptide assignment was made using
CARA v1.8.4.2 [34].
For comparison, NMR-spectra were obtained for 4-bromo-L-Trp (Amatek Chemical Co.,
Ltd., Jiangsu, China), 5-bromo-DL-Trp (Sigma-Aldrich, MO, USA), 6-bromo-DL-Trp (Bio-
synth AG, Staad, Switzerland), and 7-bromo-L-Trp (Amatek).
2.10 Data analysis and interpretation
The potential presence of peptide homologues was examined using the BLAST search engine
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) [35] on the National Centre for Biotechnological
Information (NCBI) homepage. The blastp and blastn algorithms were used, searching for
non-redundant protein sequences. Additionally, the built-in BLAST search functionality of the
LAMP database (http://biotechlab.fudan.edu.cn/database/lamp/) [36] was used. Predicted sig-
nal sequences were determined using the SignalP 4.1 server (http://www.cbs.dtu.dk/services/
SignalP/) [37] with the default setting for D-cutoff values and no TM regions selected. The
cDNA sequence and deduced amino acid sequence of sea urchins were analysed using the
BLAST program and the ExPASy Translate tool (http://web.expasy.org/translate/) with the
genetic code set to standard. Alignments using ClustalW [38] and phylogenetic trees using the
Neighbour-joining method [39] with evolutionary distances computed using the Poisson cor-
rection method [40] were constructed by the Mega 6.06 software (http://www.megasoftware.
net/) [41]. Mass spectrum predictions were performed with the ChemCalc online prediction
software (http://www.chemcalc.org/) [42] using the peptides tool with resolution set to 0.001.
Graphs were made using Graphpad Prism v 6.00 for Windows (Graphpad Software, CA,
USA). Row means, SD and linear regression was performed by the software.
2.11 Peptide synthesis
The non-brominated heavy chains (HC) of EeCentrocins 1 and 2 and the light chain (LC) of
EeCentrocin 1 were synthesised commercially (GenicBio Ltd., Shanghai, China), as were the
brominated HC of EeCentrocin 1 (HC-diBr, Isca Biochemicals, Devon, UK). The synthetic
peptides were subjected to antimicrobial activity screening and haemolytic testing as previously
described in sections 2.4 and 2.5.
The fragment, GWBrWBrR, of EeCentrocin 1 was synthesised (Isca Biochemicals) to per-
form mass spectrometric comparisons with the trypsinated N-terminal fragment of EeCentro-
cin 1. The brominated peptides were produced with both Trp residues substituted in the 6
position (i.e. 6-D/L-Trp) of the indole ring.
3 Results and Discussion
3.1 Isolation of AMPs
Antimicrobial compounds have previously been detected in the coelomic fluid and coelomo-
cytes of various echinoderms [14–16, 20, 23, 43]. In the present study, four different SPE elu-
ates obtained from an aqueous extract and one organic extract of E. esculentus coelomocytes
were tested for antibacterial activity. Of the extracts, the 40% SPE eluate displayed the highest
antibacterial activity (S1 Table). The antibacterial activity in this eluate ranged from 0.01 to
0.31 mg/ml, depending on test organism, and was therefore selected for further examinations.
Out of the four bacterial strains tested (C. glutamicum, S. aureus, P. aeruginosa and E. coli), the
Gram-positive C. glutamicum was the most sensitive overall. The 40% SPE eluate was
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fractionated by RP-HPLC and one-minute HPLC fractions were screened for activity against
the same four bacterial strains. Growth-inhibiting properties were discovered in a series of frac-
tions eluted with 20–30% ACN (Fig 2).
Three antibacterial fractions (eluting at 31, 32 and 38 min; Table 1) were further subjected
to purification by RP-HPLC and manual fraction collection. Antibacterial activity was moni-
tored on aliquots of the collected fractions during the purification process. Fraction 31 proved
Fig 2. RP-HPLC chromatogram showing the separation of AMPs in the 40% SPE fraction of E. esculentus coelomocytes. The peptides were
separated using a preparative C18 column using a flow rate of 8 ml/min, and an optimised HPLC gradient protocol of 0.05% TFA/ACN in 0.05% TFA/H2O for
60 min. One-minute fractions were collected and tested for antibacterial activity. Antibacterial fractions are marked with a black line under the chromatogram
and peak fractions selected for further analysis are marked with arrows.
doi:10.1371/journal.pone.0151820.g002
Table 1. Peptide fractions with corresponding retention times (min) obtained by preparative RP-HPLC, monoisotopic masses (Da) of the native
peptides obtained by HR-MS, and the partial amino acid sequences obtained by Edman degradation analysis. X denotes unidentified amino acids.
Peptide fraction Retention time (min) Mass (Da) Amino acid sequence
Ee4635/Ee5024 31 4630.17/5019.38 Seq 1: XGGKTXGKIKHAARKGVGYASRGCRIAGH
Seq 2: XGHKLRSSXNKVKHAVKKGAGYASGACRVLGH
Ee5922 32 5917.77 Seq 3: XNPFKKIAHRXCYPKNE
Seq 4: RXACTVVAQ
Ee4835 38 4830.20 Seq 5: GXXRRTVDKVRNAGRKVAGFASKACGALGH
Seq 6: DIGKYCGYAHALN
doi:10.1371/journal.pone.0151820.t001
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challenging to purify and after several repeated attempts to isolate the bioactive compound(s),
only a semi-pure fraction was obtained. The fraction contained two peptides in an approximate
5:1 proportion with MW of 4635 and 5024 Da respectively (S1A Fig). Fraction 32 contained a
5922 Da peptide (S1B Fig) and fraction 38 contained a peptide with MW of approximately
4835 Da (S1C Fig). The purity of the peptides was monitored by absorbance at 220 nm and ver-
ified with LC-PDA-MS. The three peptide fractions were tentatively named Ee4635/Ee5024,
Ee5922 and Ee4835 based on the MW of the most abundant peptides (See Fig 2 for chromato-
gram). Mass determination by HR-MS indicated the monoisotopic masses to be 4630.17,
5019.38, 5917.77, and 4830.20 Da, respectively (S2 Fig and Table 1).
3.2 Primary structure elucidation
Edman degradation. An aliquot of each peptide fraction was reduced, alkylated and
sequenced by Edman degradation. The analysis revealed multiple signals of amino acids of simi-
lar intensity in each position of the peptide fractions Ee4835 and Ee4635/Ee5024, suggesting that
these fractions contained peptides composed of more than one peptide chain. The reduced and
alkylated peptides were therefore subjected to RP-HPLC purification and successive Edman deg-
radation of each chain. The analysis revealed that the peptide Ee4835 seems to have a heterodi-
meric structure, containing a heavy chain (HC) composed of 30 amino acids (Seq 5, Table 1) and
a light chain (LC) composed of 13 amino acids (Seq 6, Table 1), possibly connected via a single
disulphide bond. Additionally, the analysis exposed uncommon or modified residues (X) in posi-
tions two and three of the HC. Analysis of Ee4635/Ee5024 returned two sequences with similarity
to the HC of Ee4835, probably belonging to the two different peptides known to be in the sample.
The main peptide (Ee4635 giving rise to the largest signal intensity both in MS analysis and dur-
ing sequencing) consisted of 29 amino acids (Seq 1, Table 1). Minor but distinct signals were also
recorded for a 32 amino acid peptide (Seq 2, Table 1). Both peptide sequences contained a single
cysteine residue and had uncommon or otherwise modified amino acids in different positions: 1
and 6 for Ee4635 and 1 and 9 for Ee5024. Although the HPLC chromatogram of the alkylated
peptide fraction displayed additional peaks, no other sequences were obtained. This indicates
that additional peptide fragments were present, but N-terminally blocked. Edman degradation
analysis of Ee5922 revealed a partial 17 amino acid N-terminal sequence (Seq 3, Table 1). Enzy-
matic treatment with endoproteinase Arg-C and subsequent purification and sequencing of
cleavage products revealed an additional 9 amino acid sequence (Seq 4, Table 1). The obtained
amino acid sequences formed the basis for cDNA library construction.
Characterization of cDNA sequences. To elucidate the complete peptide sequences,
degenerated primers were designed according to the partial primary peptide sequences. The
constructed 3’ RACE-Ready cDNA library was employed as template to amplify the 3’-end of
the transcripts. Three partial cDNA clones of ~320 bp, ~400 bp and ~370 bp were cloned and
sequenced. These encoded the C-terminal end of the purified peptides Ee4835, Ee5024 and
Ee5922 respectively. No cDNA sequence matching Ee4635 was found. Using the 5’RACE-PCR
approach, 5’ end cDNA sequences of Ee4835, Ee5024 and Ee5922 were cloned. The cDNA of
Ee4835 was 660 bp in length with an open reading frame of 360 bp encoding a polypeptide of
119 amino acids (Fig 3). The theoretical pI and MW of the Ee4835 precursor were calculated to
be 5.18 and 13040.0 Da respectively. The cDNA of Ee5024 was 676 bp in length with an open
reading frame of 366 bp encoding a polypeptide of 121 amino acids (Fig 3). The theoretical pI
and MW of the Ee5024 precursor were calculated to be 5.69 and 13151.1 Da respectively. The
cDNA of Ee5922 was 675 bp in length with an open reading frame of 267 bp encoding a poly-
peptide of 89 amino acids (Fig 4). The theoretical pI and MW of the Ee5922 precursor was cal-
culated to be 8.58 and 10297.96 Da respectively.
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Fig 3. Multiple sequence alignment of Ee4835 and Ee5024 with homologues in S. droebachiensis and S. purpuratus. In the aligned sequences, grey
indicates identical amino acids. The predicted signal peptides, propeptides and mature peptides are marked with curly brackets. Gaps are inserted to
maximise similarity. In the top row, accession numbers are given in parentheses, the mature peptide sequences are presented in the bottom rows.
doi:10.1371/journal.pone.0151820.g003
Fig 4. Multiple sequence alignments of Ee5922 with homologues in S. droebachiensis and S. purpuratus. In the aligned sequences, grey indicates
identical amino acids. The predicted signal peptides, propeptides and mature peptides are marked with curly brackets. Gaps are inserted to maximise
similarity. In the top row accession numbers are given in parentheses, the mature peptide sequences are presented in the bottom rows.
doi:10.1371/journal.pone.0151820.g004
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Based on the deduced amino acids from cDNA analysis, the non-identified amino acids
during Edman degradation sequenced in the two peptides Ee4835 and Ee5024 were found to
be Trp residues. The N-terminal amino acid in the peptide Ee5922 was also shown to be Trp.
Since Trp is normally detected during Edman degradation, these Trp-residues are likely modi-
fied. The precursor molecules of the peptides Ee4835 and Ee5024 have preprosequences. Anal-
ysis with SignalP 4.1 using the neural network model with SignalP-noTM setting showed that
the highest calculated cutoff value was located between positions 20 and 21 in the N-terminal
sequence of both proteins. Therefore, the predicted signal peptides consist of the 20 N-terminal
amino acids followed by a prosequence of 30 amino acids (Fig 3). The native peptides with a
proposed dimeric structure start at Gly-51 in Ee4835 and Trp-51 in Ee5024. A 24 amino acid
interchain sequence separates the HCs from the LCs and is not present in the mature peptides.
The two interchains (belonging to Ee4835 and Ee5024) are very similar, differing in only one
amino acid residue. The LCs of both peptides seem to consist of 15 amino acids and both pep-
tides contain a C-terminal dipeptide (Gly-Arg) which, based on Edman degradation and MW
data, is cleaved of. The theoretical pI of the deduced mature peptides was 10.04 for both, indi-
cating a cationic character. In silico analysis of the peptide Ee5922 suggested that the first 22
amino acids represent a signal peptide followed by a prosequence containing 16 amino acids
(Fig 4). The native, cysteine-rich peptide starts at Trp-39.
All peptides discovered in the present study have an abundance of positively charged amino
acids (23–29%) and hydrophobic amino acids (29–42%). This indicates that these sequences
are cationic and have the possibility to form an amphipathic structure, a feature which is com-
mon for most AMPs and considered important for their antimicrobial activity [2, 44–48].
Their positive charge will aid in the electrostatic attraction between the peptide and the anionic
microbial membranes [49–52]. Distributing positively charged residues on one side and hydro-
phobic residues on the other side of the structure (i.e. amphipathic), allows the peptide to
incorporate itself into and act on the bacterial membranes, as suggested by several authors [2,
45, 52]. All three peptides contain Trp residues which are considered especially important for
peptide hydrophobicity and the interactions in the membrane-water interface [48].
3.3 Homology searches and bioinformatics
BLAST searches performed on the deduced full-length amino acid sequences of Ee4835,
Ee5024 (Fig 3) and Ee5922 (Fig 4) revealed homology to the centrocins and strongylocins iso-
lated from S. droebachiensis [14, 23]. Several putative proteins in S. purpuratus were also found
to be homologues of the Ee-peptides. Due to their apparent similarity with centrocins and
strongylocins (strongylocin 2 primarily), the names EeCentrocin 1 (Ee4835) and 2 (Ee5024)
and EeStrongylocin 2 (Ee5922) are proposed for the peptides characterised in the present
study. For clarity, the originally characterised centrocins and strongylocins (from S. droeba-
chiensis) will be referred to as SdCentrocins and SdStrongylocins for the remainder of this
paper.
Alignment of EeCentrocins, SdCentrocins and predicted homologues in S. purpuratus dis-
plays high similarity in the preprosequence region (58–67%) and in the interchain regions (58–
79%), but not in the HC or LC regions (Fig 3) which display a much greater individual diver-
sity. This suggests that the HCs and LCs are subject to a much higher mutation rate and that
the signal sequences and pro sequences are more conserved regions. The partial peptide
sequence of Ee4635 did not return any homologous sequences using NCBI BLAST search anal-
ysis. However, analysis performed by the built-in BLAST search engine of the LAMP database
revealed low (E-value of 0.59) but significant homology to SdCentrocin 1. Based on the fact
that the sequence also contains one cysteine residue, unidentified or modified residues and an
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abundance of positively charged and hydrophobic amino acids, it could be hypothesised that
this peptide too belongs to the diverse heavy chains of the centrocins.
In silico analysis of the complete EeCentrocin sequences indicates that the first 20 amino
acids in the precursors function as signal peptides. Furthermore, the data show that the precur-
sor molecules have a first prosequence region of 30 amino acids, followed by a heavy chain
sequence (30 and 32 amino acids for EeCentrocin 1 and 2 respectively), a second prosequence
region of 24 amino acids (interchain), a light chain sequence of 15 amino acids and finally a
prosequence consisting of two amino acids. The function of these prosequences is unknown,
but they might aid in proper folding of the active peptides and/or function as a target for site-
specific proteases [23, 53].
Alignment of EeStrongylocin 2, SdStrongylocins and predicted homologues in S. purpuratus
(Fig 4) displays similarities in the presequence region (50–59%), the prosequence region (12–
50%) and in the mature peptide (40–84%). EeStrongylocin 2 displays greatest identity with
SdStrongylocin 2a and 2b (68–69%). In silico analysis defined the first 22 N-terminal amino acids
as the signal peptide, leaving a 16 amino acid prosequence before the mature peptide. As centro-
cin-like and strongylocin-like peptide sequences have been discovered in three species of sea
urchins, the possibility of them being a trait of this class of echinoderms exist, increasing the pos-
sibility of discovering other homologous bioactive peptides in other species of sea urchins.
Fig 5 represents the phylogenetic trees composed of all homologues found in S. droebachien-
sis and S. purpuratus by BLAST searches. It appears that the EeCentrocins (Fig 5A) are phylo-
genetically separated from the other peptides, sharing one common ancestor with all. The
SdCentrocins are more closely related to the predicted centrocin-like proteins in S. purpuratus.
The SdStrongylocin 1 and 2 AMPs seem to be separated phylogenetically (Fig 5B) but share a
common ancestor. EeStrongylocin 2 aligns more closely with SdStrongylocin 2. The S. purpur-
atus genome has been completely sequenced [54] whereas only a few proteins from S. droeba-
chiensis and E. esculentus have been sequenced. It is therefore unknown whether the two
species E. esculentus and S. droebachiensis contain additional strongylocin-like and centrocin-
like peptides or not, and explains the excess of sequences from S. purpuratus in the figures.
3.4 Characterisation of post-translational modifications
The theoretical monoisotopic mass of EeCentrocin 1 (deduced from cDNA) containing an
intramolecular disulphide bond was calculated to be 4675.37 Da, leaving a gap of 154.83 Da to
the native isolated peptide (4830.20 Da). In order to identify the modifications of the second
and third amino acids (both being Trp residues according to cDNA), the peptide was degraded
by trypsin and analysed by HR-MS. The mass value of the major fragment and its correspond-
ing isotope distribution of [M+H]+ ions (Fig 6A) agreed well with the ion distribution of the
synthetically produced fragment GWBrWBrR (Fig 6B) and a theoretical ion distribution of
[GWBrWBrR+H]
+ (Fig 6C), indicated that the peptide contains two brominated Trp residues.
Seven ion peaks are clearly visible in all three figures with similar relative abundances and min-
ute differences inm/z values (See S7 Table for calculated and measuredm/z values). The pres-
ence of two Br-Trp in EeCentrocin 1 leads to a theoretical monoisotopic mass of 4831.19 Da.
This exceeds the measured mass by approximately one Da, suggesting that one of the peptide
chains is amidated at the C-terminal (4830.20 Da).
The deduced sequence of the EeCentrocin 1 LC holds a dipeptide “Gly-Arg” at the C-termi-
nal end, which resembles previously published amidation signal sequences. As shown by
HR-MS (S3 Fig), the LC of the isolated peptide is in fact amidated at the C-terminal. The tachy-
plesin precursor from the horseshoe crab (Tachypleus tridentatus) [56], aureins (excluding aur-
ein 5.3) from the frog (Litoria aurea) [57] and astacidin 2 from the fresh water crayfish
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(Pacifastacus leniusculus) [58] all contain amidation signals such as “Gly-Lys” and “Gly-Lys-
Arg” which leads to a C-terminal amidation. However in the centrocins [23] of S. droebachien-
sis, no amidation is observed despite the presence of the cleaved-off “Gly-Arg” C-terminally.
No MS data fits the theoretical monoisotopic mass (4881.56 Da) calculated from the
deduced amino acid sequence of EeCentrocin 2. Based on the findings from EeCentrocin 1 and
the bromination occurring in centrocins [23], we hypothesise that EeCentrocin 2 also has two
Fig 5. Evolutionary relationships of A) centrocins and B) strongylocins identified in E. esculentus, S. droebachiensis and S. purpuratus. The
evolutionary history was inferred using the Neighbour-joining method [39] and the optimal trees are shown. The percentage of replicate trees in which the
proteins clustered together during the bootstrap test (500 replicates) is given next to the nodes [55]. The tree is drawn to scale, with branch lengths in the
same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Poisson
correction method [40]. Accession numbers are given in parentheses.
doi:10.1371/journal.pone.0151820.g005
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post-translationally brominated Trp residues (positions 1 and 9) in the HC. This is also based
on the inability of Edman degradation to identify any residue in these positions. Adding two
bromines to the elemental composition leads to a theoretical mass of 5037.38. This deviates
from the isolated peptide by +18.00 Da, indicating the presence of additional modifications on
the isolated AMP. The deduced LC sequence of EeCentrocin 2 also contains a “Gly-Arg” ami-
dation signal, which indicates that the peptide contains an amidated His residue C-terminally.
Additionally, the LC contains an N-terminal Gln residue. The formation of pyroglutamic acid
(Glp) is known to occur both enzymatically and spontaneously [59, 60] when Gln or Glu is
located N-terminally in a peptide sequence. HR-MS and MS/MS data of the alkylated LC of
EeCentrocin 2 (S4 Fig) supports formation of both N-terminal Glp and C-terminal amidation,
leading to a theoretical monoisotopic mass of 5019.37 Da, which corresponds to the measured
mass. Glp-formation also explains why no sequence for the LC was obtained during Edman
degradation as it sequences α-amino groups [61]. In The Antimicrobial Peptide Database,
there are 19 entries with N-terminal Glp of which one is of marine origin [62]. The measured
monoisotopic mass of EeStrongylocin 2 corresponds to the amino acid sequence deduced from
cDNA. The theoretical MW of the peptide with 3 disulphide bonds is 5839.86 Da, and by
replacing an indole hydrogen with a bromine, the theoretical monoisotopic mass (5917.80 Da)
matches the experimental one (5917.77 Da). Additionally, a brominated ion atm/z 769.19
Fig 6. Characterisation of the post-translational modifications of EeCentrocin 1 HC. High-resolution
mass spectra showing them/z isotope cluster corresponding to the [M+H]+ ions of A) Main peptide fragment
from a tryptic digest of native EeCentrocin 1, B) Synthesised fragment GWBrWBrR, and C) Calculated isotope
distribution of [GWBrWBrR+H]
+. The identical and distinctive distributions (A, B and C) of the singly charged
isotopes indicate the presence of two Br-Trp residues in EeCentrocin 1.
doi:10.1371/journal.pone.0151820.g006
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emerged during LC-PDA-MS with the same retention time as EeStrongylocin 2 that probably
represent H-W(Br)NPFK-OH (S5 Fig).
NMR spectroscopy was employed to characterise the position of the bromine on the Trp
residues of the native peptides, including the two-peptide mixture of EeCentrocin 2 and
Ee4635. The native proton resonances of the brominated Trp residues of EeCentrocin 1 and
EeStrongylocin 2 were compared to those of the reference compounds 4-, 5-, 6-, and 7-Br-Trp
in water (S6 Fig). The proton coupling patterns did not match the patterns of 4- and 7-Br-Trp,
leaving 5- and 6-Br-Trp as the only viable alternatives. The chemical shifts of the peptides are
found to slightly better match with the 6-Br reference compound (average error:
0.14 ± 0.07 ppm) in comparison with 5-Br (average error: 0.16 ± 0.12 ppm). Well-resolved aro-
matic region 1H,13C-HSQC and 1H,13C-HMBC of the modified Trp residues of EeCentrocin 1
and EeStrongylocin 2 revealed the positions of the brominations (S7 Fig). The carbon chemical
shifts matched far better with reference compounds of 6-Br-Trp (Fig 7 and S7 Fig). This led to
the confirmation of, not only 6-Br-Trp in EeCentrocin 1 and EeStrongylocin 2, but also two
6-Br-Trp residues in EeCentrocin 2 where only cDNA data (displaying Trp) existed for posi-
tions 1 and 9. One other 6-Br-Trp residue was identified, likely to belong to the 6th amino acid
in Ee4635 as the chemical shifts of a 6-Br-Trp in the first position of Ee4635 would perfectly
overlap with EeCentrocin 2 due to identical N-terminals.
Marine species are well known to incorporate bromine in their secondary metabolites and
peptides [63, 64]. Bromination of Trp in the 6 position as a post-translational modification was
first reported in 1997 in toxins isolated from cone snails Conus imperialis and C. radiatus [63].
Styelin D from the marine tunicate (Styela clava) also has a confirmed 6-bromination of Trp
[65]. Several other marine organisms have brominated Trp residues but without confirmed
positioning: cathelicidins from the Atlantic hagfish (Myxine glutinosa) [49], hedistin from the
marine annelid (Nereis diversicolor) [66], strongylocin 2 and the centrocins from the green sea
urchin (S. droebachiensis) [14, 23]. The biological function of bromine-substitution of Trp is
not known, but has been suggested to aid in the proteolytic protection of the peptides [49].
No ordered structure of the centrocin-peptides in MQ-H2O and with high salt concentra-
tions has been detected during the NMR experiments. However, several peptides only adopt an
ordered structure in the presence of membranes or membrane-mimics [52]. The secondary
structure of EeStrongylocin 2 as dictated by its disulphide bonds is yet to be elucidated. The
proposed structure of the two dimeric peptides EeCentrocins 1 and 2, and the primary struc-
ture of EeStrongylocin 2 can be viewed in Fig 8.
Fig 7. Carbon chemical shifts of Br-Trp in native peptides correlated with synthetic 5-Br-Trp and 6-Br-Trp. The chemical shifts are less well correlated
for the 5-Br reference compound (left, 5.36 ppm average error) than those of the 6-Br reference compound (right, 1.55 ppm average error). Each data point in
the figure represents a carbon of the indole of Trp.
doi:10.1371/journal.pone.0151820.g007
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3.5 Bioactivities
The antimicrobial activity of the native EeCentrocin 1 was measured against four selected bac-
terial strains (Table 2, raw data in S9 Table). The peptide displayed potent antibacterial activity
against the Gram-positive bacteria, C. glutamicum and S. aureus (MIC = 0.78 μM against both)
and the Gram-negative bacteria, E. coli and P. aeruginosa (MIC = 0.1 and 0.78 μM
Fig 8. Structures of peptides discovered in E. esculentus. The two top structures are the heterodimeric EeCentrocins 1 and 2. The disulphide bonds
connecting the HC and LC are indicated with “|”. The lower sequence is the primary structure of EeStrongylocin 2. All Trp substitutions are assigned to the 6
position of the indole.
doi:10.1371/journal.pone.0151820.g008
Table 2. Antimicrobial activities of native EeCentrocin 1, EeStrongylocin 2 and synthesised analogues of EeCentrocin 1 and 2. LC = light chain,
HC = heavy chain, HC-diBr = peptide with two brominated Trp residues.
Minimum inhibitory concentration (MIC) (μM)
EeCentrocin 1 EeCentrocin 2 EeStrongylocin 2
Microorganism Native HC-diBr HC LC HC Native
Gram-positive bacteria
B. subtilis nt1 1.56 1.56 >100 6.25 nt
C. glutamicum 0.78 0.78 0.39 >100 0.78 1.56
S. aureus 0.78 3.13 3.13 >100 6.25 3.13
S. epidermidis #1 nt 6.25 6.25 >100 3.13 nt
S. epidermidis #2 nt 3.13 3.13 >100 3.13 nt
Gram-negative bacteria
E. coli #1 0.1 1.56 0.78 >100 1.56 0.78
E. coli #2 nt 1.56 1.56 >100 6.25 nt
P. aeruginosa #1 0.78 1.56 1.56 >100 0.78 1.56
P. aeruginosa #2 nt 3.13 3.13 >100 6.25 nt
Fungi
A. pullulans nt 6.25 12.5 >100 25 nt
C. albicans nt 50 100 >100 50 nt
Cladosporium sp. nt >100 >100 >100 12.5 nt
Rhodotorula sp. nt 12.5 12.5 >100 3.13 nt
S. cerevisiae nt >100 50 >100 12.5 nt
nt: not tested
doi:10.1371/journal.pone.0151820.t002
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respectively). The activity was in the same range as for the SdCentrocins [23]. Because of a
challenging purification, we were not able to perform investigations of the antibacterial potency
of the native EeCentrocin 2 and Ee4635. However, the mix of both these peptides was antibac-
terial. The antibacterial potency fluctuates enormously among amphipathic AMPs [67–69],
but EeCentrocin 1 (and the HC of EeCentrocins 1 and 2) are antimicrobial in similar ranges as
those of the SdCentrocins [23]. According to previous published work [51], this is a typical
activity range for AMPs. It has also been stated that the MIC activity range of an AMP rarely
falls below 0.5–1.0 μM [50], which is in the same MIC region as the most potent AMPs pre-
sented in this paper.
The HC of the EeCentrocins was shown to be the antimicrobial portion of the peptides, dis-
playing similar potency as the native peptide against some bacterial strains (Table 2). Interest-
ingly, the activity of the HC also appears to be independent of the bromination of the Trp
residues. The MICs of EeCentrocin 1 HC-diBr towards bacteria ranged from 0.78 to 6.25 μM
which is almost identical to the MIC displayed by EeCentrocin 1 HC (0.39–6.25 μM). The HC
of EeCentrocin 2 displayed similar antibacterial activities (MIC ranging from 0.78–6.25 μM).
The antifungal activities of the two EeCentrocin 1 HCs were also quite similar, differing only
by one dilution step, whereas EeCentrocin 2 HC seems to be a slightly more potent antifungal
agent. The LC (synthesised with a C-terminal carboxyl group) of EeCentrocin 1 is of no observ-
able importance to antimicrobial activity, when comparing the native peptide with the dibro-
minated or nonbrominated HCs, and it is not antimicrobial when tested alone. This supports
our previous studies on the LC of the SdCentrocins [23] and suggests other tasks for the LC.
Whether a C-terminally amidated peptide (increasing the charge by +1) would have displayed
antimicrobial activity is uncertain.
The MIC of native EeStrongylocin 2 was found to range from 0.78 to 3.13 μM against the
tested strains. The SdStrongylocins displayed similar antibacterial activity with MICs ranging
from 2.5 to 5 μM [14]. The two recombinantly produced peptides, SpStrongylocins 1 and 2
(originating from S. purpuratus) displayed MICs towards the same strains at 15 and 7.5 μM
respectively [24].
The synthesised EeCentrocin 1 (HC, HC-diBr and LC) peptide analogues displayed no or
minor haemolytic activity at a concentration of 100 μM (Fig 9, raw data in S10 Table), a con-
centration which is 16 times higher than the MIC against the least sensitive bacteria (Staphylo-
cocci) tested in this study. No or minor haemolytic activity is a prerequisite if the peptides are
ever to be exploited clinically or as food additives [70]. EeCentrocin 2 HC was more haemoly-
tic, displaying 11.7, 18.9 and 56.3% haemolysis at concentrations 25.0, 50.0 and 100 μM,
respectively. The reason for this higher haemolytic activity of EeCentrocin 2 compared to
EeCentrocin 1 is unclear. However, increasing physicochemical parameters like hydrophobic-
ity and hydrophobic face are known to enhance the haemolytic activity of α-helical AMPs [71].
4 Conclusion
The widespread use of antibiotics and the associated development of microbial resistance to
these drugs has emerged as a major global problem. The search for new antibacterial agents has
therefore become an important area in natural product drug discovery. Cationic AMPs have
previously been isolated from various species and phyla, and represent a novel class of antibiot-
ics. In this study, potent AMPs were for the first time characterised from coelomocyte extracts
of the Edible sea urchin, E. esculentus, collected from sub-Arctic waters. Three 5–6 kDa AMPs
were shown to be novel members of the centrocin and strongylocin families of AMPs. The
EeCentrocins have a heterodimeric structure composed of a heavy chain and a light chain con-
nected by a single disulphide bond. Neither the presence of brominated amino acids in the
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heavy chain nor a light chain with C-terminal amidation and N-terminal pyroglutamic acid
seem to be necessary for maintaining antibacterial activity, but these additional structures
might aid in the protection against proteolytic degradation of the peptides. The secondary
structure and the three-dimensional conformation of EeStrongylocin 2 as dictated by its three
disulphide bonds remains unknown, but should be explored. Future research should also
include mode of action studies, where cellular targets are identified, and structure-activity rela-
tionship studies where truncated analogues of the EeCentrocin HCs are constructed in order to
pinpoint the pharmacophore. Additionally, as it appears that sea urchins in general are produc-
ers of strongylocins and centrocins, a genomic approach to discover homologues in other sea
urchins (or echinoderms) for the discovery of novel AMPs could be a beneficial venture.
This study has demonstrated that marine invertebrates are a valuable resource for discover-
ing unique bioactive peptides, providing promising leads for development of novel antimicro-
bial drugs.
Fig 9. Haemolytic activity of synthetic analogues of EeCentrocin 1 and 2. The different synthetic peptide analogues of EeCentrocin 1 and 2 display
minor haemolytic activity in concentrations up to 12.5 μM. EeCentrocin 2 HC displays the highest haemolytic activity (56.4% haemolysis at 100 μM).
doi:10.1371/journal.pone.0151820.g009
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Supporting Information
S1 Fig. ESI-MS spectra of A) native Ee4635 (M1) and Ee5024 (M2), B) native Ee5922 and
C) native Ee4835. The peptide Ee4635 revealed multiple ions atm/z 773.61 [M1 + 6H]
6+,
927.95 [M1 + 5H]
5+, 1159.65 [M1 + 4H]
4+, and 1545.93 [M1 + 3H]
3+, indicating that the pep-
tide has a MW of approximately 4635 Da. The peptide Ee5024 revealed multiple ions atm/z
838.30 [M2 + 6H]
6+, 1005.92 [M2 + 5H]
5+, 1257.06 [M2 + 4H]
4+, and 1675.61 [M2 + 3H]
3+,
indicating that the peptide has a MW of approximately 5024 Da. ESI-MS of Ee5922 revealed
multiple ions at m/z 741.37 [M + 8H]8+, 847.03 [M + 7H]7+, 988.01 [M + 6H]6+, 1185.47
[M + 5H]5+, 1481.69 [M + 4H]4+, and 1975.09 [M + 3H]3+, indicating that the peptide has a
MW of approximately 5922 Da. ESI-MS of Ee4835 revealed multiple ions at m/z 691.73
[M + 7H]7+, 806.74 [M + 6H]6+, 968.01 [M + 5H]5+, 1209.68 [M + 4H]4+, and 1612.72
[M + 3H]3+, indicating that the peptide has a MW of approximately 4835 Da.
(EPS)
S2 Fig. HR-MS spectra of the [M+5H]5+ ions of A) Ee4635, B) Ee5024, C) Ee4835 and the
[M+6H]6+ ion of D) Ee5922.
(EPS)
S3 Fig. HR-MS spectrum of the [M+2H]2+ ion of the alkylated (4-vinylpyridine) LC of
EeCentrocin 1. The measuredm/z (764.87) corresponds with the LC containing a C-terminal
amidation (theoreticalm/z 764.87).
(EPS)
S4 Fig. HR-MS of the alkylated (4-vinylpyridine) EeCentrocin 2 LC A) [M+H]+ ion, and B)
MS/MS spectrum of the expected a2 and b2 ions. The measuredm/z (1483.76) corresponds
with the LC containing a C-terminal amidation and an N-terminal Glp (theoreticalm/z
1483.77). The MS/MS spectrum supports the formation of Glp with the a2 ion atm/z 183.11
and b2 ion atm/z 211.11.
(EPS)
S5 Fig. ESI-MS spectrum of a brominated ion possibly representing the N-terminal
sequence H-W(Br)NPFK-OH of EeStrongylocin 2. The fragment appeared in the same MS
spectrum as EeStrongylocin 2 during LC-PDA-MS. The measuredm/z (769.2) on low-resolu-
tion MS corresponds with the theoreticalm/z (769.3).
(EPS)
S6 Fig. NMR assignment of the 6-Br-Trp residues of native EeCentrocin 1, EeStrongylocin
2 and brominated reference compounds. A-D) 1H spectra of the reference compounds 4, 5, 6
and 7-Br-Trp, E) native EeCentrocin 1 and F) EeStrongylocin 2 with putative assignments for
the two Br-Trp residues compared to the reference compounds positions.
(EPS)
S7 Fig. 6-Br-Trp carbon assignments in superimposed HSQC and HMBC spectra. A) Refer-
ence compound 6-Br-Trp, B) Reference compound 5-Br-Trp, C) EeCentrocin 1, D) EeCentro-
cin 2, E) Ee4635 and F) EeStrongylocin 2.
(EPS)
S1 Table. Antibacterial activity of SPE eluates and the organic phase of E. esculentus coelo-
mocytes against Gram-positive and Gram-negative bacteria.
(XLSX)
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S2 Table. MS experiment and parameters. The experiments used for mass spectrometry are
listed for low resolution above and high resolution below.
(XLSX)
S3 Table. Overview of primers used in this study.
(XLSX)
S4 Table. NMR experiments and acquisition parameters for synthetic EeCentrocin 1 HC-
diBr collected in H2O:D2O 9:1.
(XLSX)
S5 Table. NMR experiments and acquisition parameters for the native EeCentrocin 1 col-
lected in D2O.
(XLSX)
S6 Table. NMR experiments and acquisition parameters for the native Ee4635/EeCentrocin
2 mix and EeStrongylocin 2 collected in D2O.
(XLSX)
S7 Table. Predicted and measuredm/z values of the GW(Br)W(Br)R fragment of EeCentro-
cin 1.
(XLSX)
S8 Table. Backbone and side chain assignment of synthetic EeCentrocin 1 HC-diBr. The
table depicts chemical shifts of the synthetic HC-diBr.
(XLSX)
S9 Table. Raw data from antimicrobial activity testing. Grey highlights are the values
exported to the table displayed in the manuscript.
(XLSX)
S10 Table. Raw data from haemolytic assay showing absorbance at 550 nm.Mean values are
exported to the figure used in the manuscript.
(XLSX)
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